ホーム>>Signaling Pathways>> Metabolism>> PDE>>SDZ-MKS 492

SDZ-MKS 492 (Synonyms: MKS 492)

カタログ番号GC65302

SDZ-MKS 492 (MKS 492) は、サイクリック GMP 阻害ホスホジエステラーゼ (タイプ III PDE) の選択的阻害剤です。

Products are for research use only. Not for human use. We do not sell to patients.

SDZ-MKS 492 化学構造

Cas No.: 114606-56-3

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$346.50
在庫あり
5mg
$315.00
在庫あり
10mg
$495.00
在庫あり
50mg
$1,485.00
在庫あり
100mg
$2,025.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SDZ-MKS 492 (MKS 492) is a selective inhibitor of cyclic GMP-inhibited phosphodiesterase (type III PDE). SDZ-MKS 492 inhibits antigen- or platelet activating factor (PAF)-induced bronchoconstriction and allergic reactions in guinea pigs and rats[1].

MKS 492 relaxes airway smooth muscle in vitro[2].

MKS-492 (3-10 mg/kg; i.v.) inhibits antigen-induced bronchoconstriction in guinea pigs[1].MKS-492 (1-3 mg/kg; i.v.) inhibits PAF-induced bronchoconstriction and the increase in airway responsiveness to histamine in guinea pigs[1].MKS-492 (30-100 mg/kg; i.p.) inhibits leukotriene B4 (LTB4)-induced airway eosinophilia in guinea pigs[1].MKS-492 (10-100 mg/kg; i.p.) inhibits passive cutaneous anaphylaxis and mediator-induced skin reactions in rats[1].

[1]. Nagai H, et al. Effects of MKS-492 on antigen-induced bronchoconstriction and allergic reaction in guinea pigs and rats. Jpn J Pharmacol. 1993 Dec;63(4):405-13.
[2]. Morley J, et, al. SDZ MKS 492. Agents Actions Suppl. 1991;34:403-10.

レビュー

Review for SDZ-MKS 492

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SDZ-MKS 492

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.